| My Account | Subscribe | Contact Us | Donate |
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Type 2 Issues Articles
Who would have guessed that taking two diabetes drugs combined in one tablet would offer greater glucose-lowering benefits than taking the same two drugs in separate but still co-administered tablets?
A glyburide/metformin tablet, marketed in the United States as Glucovance, delivered a significantly greater reduction in A1C than a prior regimen of glyburide co-administered with metformin.
According to a study from Bristol-Myers Squibb and the Ochsner Clinic Foundation in New Orleans, the effect was especially significant when a patient’s baseline A1C level was 8%.
The therapy was tested in 950 patients—471 of whom received glyburide co-administered with metformin. The average A1C decrease for the combination tablet group was 2.02%, compared with a decrease of 1.49% for glyburide co-administered with metformin, despite the fact that the patients receiving the combination tablet received lower doses of the medications.
The study data were obtained from retrospective pharmacy claims data and corresponding laboratory results from a usual-care setting.
Diabetes, Obesity and Metabolism, November 2003
Categories: Metformin, Type 2 Issues, Type 2 Medications
Mar 1, 2004 - Not Yet Rated
Email to a Friend
Send a link to this page to your friends and colleagues.